ASCO 2024: Latest Data in Melanoma : Episode 1
Opinion
Video
ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Now Viewing
EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management
EP: 2.Key Findings from the NADINA Trial at ASCO 2024
EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management
EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma
EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma
EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma
EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights
Video content above is prompted by the following:
- Coming into ASCO 2024, what would did consider to be the largest unmet needs in the treatment and management of melanoma?
- What are the latest trends and innovations you have observed in the treatment and management of melanoma leading up to and coming out of ASCO 2024?
Related Videos
Related Content
